In the 2nd quarter of 2021, Deerfield co-led a $107.5M Series B Preferred crossover financing for Synthekine. Synthekine is focused on engineered cytokine therapeutics and novel synthetic cytokines (called synthekines) based on the research of Christopher Garcia, Professor of Molecular and Cellular Physiology and Structural Biology at Stanford University School of Medicine and a renowned expert in cytokine biology. The Company has two lead programs both focused on cancer with IND filings planned for 2021.